| COMVAX is indicated for vaccination
against invasive disease caused by Haemophilus influenzae type
b and against infection caused by all known subtypes of hepatitis
B virus in infants 6 weeks to 15 months of age born to HBsAg-negative
mothers. COMVAX should be administered at 2, 4, and 12 to 15
months of age. COMVAX should not be administered to any infant
before the age of 6 weeks.
Select safety information
COMVAX is contraindicated in patients with hypersensitivity
to yeast or any component of the vaccine. Persons who develop
symptoms suggestive of hypersensitivity after an injection
should not receive further injections of the vaccine.
As with other vaccines, COMVAX may not induce protective
antibody levels immediately following vaccination and may
not result in a protective antibody response in all individuals
given the vaccine.
In clinical trials, the most common nonserious adverse experiences
observed in >1% of children receiving COMVAX included
injection-site reactions, somnolence, irritability, crying,
and fever (>101° F); for a listing of adverse
reactions, please read the Prescribing Information.
Before administering COMVAX, please read the Prescribing
Information.
Continue to Hib antibody
response.
References: 1. American
Academy of Pediatrics Committee on Infectious Diseases. Haemophilus
influenzae type b conjugate vaccines: recommendations for
immunization with recently and previously licensed vaccines. Pediatrics.
1993;92:480–488. 2. Data available
on request from Merck & Co., Inc., Professional Services—DAP,
WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify
information package 20702823(1)-CVX. |
